Clinical Trials
Numerous clinical trials evaluate uric acid and urate-related physiological pathways across conditions including hyperuricemia, gout, uric acid nephrolithiasis, hypertension, and metabolic disorders. Spanning Early Phase 1 through Phase 4 alongside unassigned interventional studies, these protocols—encompassing active, recruiting, completed, and withdrawn statuses—are sponsored by major academic and clinical institutions such as Johns Hopkins University and Seoul National University Hospital. Specific interventions assessed include dietary regimens for elevated serum urate, probiotic supplementation for gout, and urinary alkalinization for urate stone management.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07613164 | NOT_YET_RECRUITING | Hyperuricemia, Gout |
Maanshan Shiqiye Hospital |
2026-05 | |
| NCT07326839 | NOT_YET_RECRUITING | Gout; Obesity |
XueMei Guo |
2025-12-10 | |
| NCT07650214 | NOT_YET_RECRUITING | Asymptomatic Hyperuricemia |
Sun Yat-sen University |
2026-07-01 | |
| NCT04026776 | RECRUITING | Salt; Excess; Blood Pressure Disorders |
Wake Forest University Health Sciences |
2020-09-02 | EARLY_PHASE1 |
| NCT06824376 | RECRUITING | Asymptomatic Hyperuricemia |
Shenghao Tu |
2025-03-25 | |
| NCT06335537 | RECRUITING | Uric Acid Stones |
University of California, Irvine |
2025-05-01 | PHASE1 |
| NCT04745910 | COMPLETED | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Tumor Lysis Syndrome |
M.D. Anderson Cancer Center |
2022-04-05 | PHASE4 |
| NCT06966635 | RECRUITING | Hyperuricemia or Gout; Nephrolithiasis |
Huashan Hospital |
2024-04-10 | PHASE4 |
| NCT07076888 | RECRUITING | Hemodialysis |
Cairo University |
2025-08-01 | |
| NCT06187519 | COMPLETED | Gout |
University of California, Los Angeles |
2025-03-10 | |
| NCT04370093 | COMPLETED | Nephrolithiasis, Uric Acid |
University of Texas Southwestern Medical Center |
2019-10-17 | PHASE4 |
| NCT04621929 | COMPLETED | Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes |
University of Florida |
2021-03-31 | PHASE2 |
| NCT06621589 | COMPLETED | Obesity |
RS H Adam Malik |
2024-08-26 | |
| NCT05298891 | Not yet recruiting | Acromegaly |
Azienda Ospedaliero Universitaria Maggiore della Carita |
2024-09-01 | Not Applicable |
| NCT05745727 | COMPLETED | Gout |
Protalix |
2023-03-23 | PHASE1 |
| NCT06126315 | Not yet recruiting | Amyotrophic Lateral Sclerosis |
Mario Negri Institute for Pharmacological Research|University of Sydney|FightMND |
2024-06 | Phase 2|Phase 3 |
| NCT06177821 | Recruiting | Prostatic Hyperplasia of the Medial Lobe |
Seoul National University Hospital |
2024-06-03 | Not Applicable |
| NCT06335537 | Not yet recruiting | Uric Acid Stones |
University of California Irvine |
2024-05 | Phase 1 |
| NCT06084585 | UNKNOWN | Hyperuricemia |
Amway (China) R&D Center |
2023-10-23 | |
| NCT05402397 | COMPLETED | Uric Acid Nephropathy |
Hospital General de Niños Pedro de Elizalde |
2022-07-01 | PHASE4 |
| NCT05496075 | COMPLETED | Uric Acid |
Shanghai 10th People's Hospital |
2022-08-26 | PHASE4 |
| NCT04199325 | UNKNOWN | Gout; Hyperuricemia |
The Affiliated Hospital of Inner Mongolia Medical University |
2018-11-01 | |
| NCT03899883 | COMPLETED | Diabetic Kidney Disease; Hyperuricemia; Diabetes; Diabetes Mellitus, Type 2; Type2 Diabetes; Type 2 Diabetes Mellitus; Diabetic Nephropathies; Diabetes Complications |
University of Colorado, Denver |
2020-01-01 | PHASE2 |
| NCT04316390 | COMPLETED | Higher Uric Acid Concentrations (>5,5 mg/dl); Healthy |
University of Kiel |
2022-07-15 | |
| NCT05226013 | UNKNOWN | Hyperuricemia |
The Affiliated Hospital of Qingdao University |
2021-12-08 | PHASE1 |
| NCT04772313 | COMPLETED | Uncontrolled Gout |
Amgen |
2021-03-08 | PHASE4 |
| NCT03648996 | COMPLETED | Diabetes Mellitus, Type 2; Hyperuricemia |
University of Missouri-Columbia |
2018-11-01 | PHASE2 |
| NCT04960527 | COMPLETED | Uric Acid; Cardiovascular Diseases; Gout |
Sheffield Hallam University |
2021-07-10 | |
| NCT04772352 | UNKNOWN | Nonalcoholic Fatty Liver Disease |
Ningbo No. 1 Hospital |
2021-03-01 | PHASE2 |
| NCT05210517 | COMPLETED | Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2020-10-01 | PHASE4 |
| NCT04837274 | COMPLETED | Health Services Research |
Texas A&M University |
2020-04-10 | |
| NCT03865407 | TERMINATED | Hyperuricemia; Chronic Kidney Diseases |
Virginia Commonwealth University |
2019-03-10 | PHASE2 |
| NCT05967754 | COMPLETED | Obstructive Sleep Apnea |
Alexandria University |
2018-01-01 | |
| NCT04352153 | UNKNOWN | Uric Acid Stones; Hyperuricemia |
Ai Peng |
2020-04-01 | |
| NCT02975986 | WITHDRAWN | Uric Acid Nephrolithiasis |
University of Texas Southwestern Medical Center |
2017-01 | |
| NCT04165499 | COMPLETED | Hyperuricemia |
Biosearch S.A. |
2019-11-11 | EARLY_PHASE1 |
| NCT03395977 | COMPLETED | Oxidative Stress; Endothelial Function; Cardiovascular System; Hypertension |
Erasme University Hospital |
2018-01-03 | |
| NCT02891031 | UNKNOWN | Hyperuricemia |
Shiraz University of Medical Sciences |
2019-06-01 | |
| NCT03569020 | COMPLETED | Gout; Hyperuricemia |
Johns Hopkins University |
2018-08-07 | |
| NCT03403309 | COMPLETED | Multiple System Atrophy |
Yonsei University |
2018-05-02 | PHASE2 |
| NCT03658317 | UNKNOWN | Diabetic Nephropathy |
Assiut University |
2018-09 | |
| NCT03226899 | TERMINATED | Gout; Chronic Kidney Disease (CKD) |
Ironwood Pharmaceuticals, Inc. |
2017-07-19 | PHASE4 |
| NCT03939130 | COMPLETED | Fructose Metabolism Disorder; Fructose Rich Diet; Metabolic Disease; Aerobic Exercise |
Federal University of Rio Grande do Sul |
2018-06-01 | |
| NCT03076684 | WITHDRAWN | Hyperuricemia |
University of Missouri-Columbia |
2017-03-03 | EARLY_PHASE1 |
| NCT02959918 | COMPLETED | Gout Chronic; Hyperuricemia |
Selecta Biosciences, Inc. |
2016-10 | PHASE2 |
| NCT03118739 | COMPLETED | Hyperuricemia; Albuminuria; Type 2 Diabetes |
AstraZeneca |
2017-05-18 | PHASE2 |
| NCT03306758 | UNKNOWN | Asymptomatic Hyperuricemia; Gout |
Shanghai Zhongshan Hospital |
2017-11-01 | |
| NCT03316131 | COMPLETED | Asymptomatic Hyperuricemia |
AstraZeneca |
2017-10-25 | PHASE2 |
| NCT03568864 | COMPLETED | Healthy |
University of Exeter |
2017-07-31 | |
| NCT03211403 | COMPLETED | Gout; Hyperuricemia |
Atridia Pty Ltd. |
2017-07-04 | PHASE1 |
| NCT02129764 | COMPLETED | Heart Failure, Hyperuricemia |
Hebei Medical University |
2013-12 | PHASE2; PHASE3 |
| NCT02644486 | TERMINATED | Obesity and Glomerulopathy |
Zhi-Hong Liu, M.D. |
2016-01 | |
| NCT03531203 | COMPLETED | Blood Pressure; Prehypertension; Uric Acid |
Gadjah Mada University |
2017-07-10 | |
| NCT03218709 | UNKNOWN | Hyperuricemia |
Sun Yat-sen University |
2017-01 | PHASE4 |
| NCT02984358 | COMPLETED | Healthy |
University of Exeter |
2017-01 | |
| NCT00904046 | COMPLETED | Uric Acid Kidney Stone Disease |
University of Texas Southwestern Medical Center |
2010-01-15 | |
| NCT03512600 | COMPLETED | Lithiasis, Urinary |
Devicare S.L. |
2017-09-04 | |
| NCT02563405 | UNKNOWN | Hypertension |
First Affiliated Hospital of Harbin Medical University |
2015-09 | PHASE2; PHASE3 |
| NCT02502071 | COMPLETED | Type 1 Diabetes; Diabetic Nephropathy; Diabetic Kidney Disease |
University of Colorado, Denver |
2017-01 | PHASE4 |
| NCT02648269 | COMPLETED | Gout |
Selecta Biosciences, Inc. |
2015-12 | PHASE1 |
| NCT02797028 | UNKNOWN | Cardiovascular Disease |
Guangzhou General Hospital of Guangzhou Military Command |
2015-01 | PHASE4 |
| NCT01228903 | COMPLETED | Kidney Disease |
University of Colorado, Denver |
2010-10 | |
| NCT02561858 | COMPLETED | Uric Acid Stones |
Centre Hospitalier Universitaire de Nice |
2015-10-14 | |
| NCT02464605 | COMPLETED | Gout |
Selecta Biosciences, Inc. |
2015-05 | PHASE1 |
| NCT02344602 | COMPLETED | Type 1 Diabetes Mellitus |
University Health Network, Toronto |
2012-12-18 | PHASE4 |
| NCT02063997 | COMPLETED | Gout |
Gilead Sciences |
2014-03 | PHASE2 |
| NCT01510769 | COMPLETED | Tophaceous Gout |
Ardea Biosciences, Inc. |
2012-01 | PHASE3 |
| NCT01881919 | COMPLETED | Hyperuricemia; Gout; Kidney Calculi; Diabetes; Cardiovascular Disease |
University of Leeds |
2013-02 | EARLY_PHASE1 |
| NCT01472692 | COMPLETED | Prehypertension; Gout; Pulse Wave Velocity; Hypertension; 24 Hour Blood Pressure |
University of California, San Diego |
2011-10 | PHASE4 |
| NCT01323335 | COMPLETED | Healthy Volunteers |
National Institute on Aging (NIA) |
2009-03-31 | PHASE1 |
| NCT01532622 | COMPLETED | Hyperuricemia |
University of Mississippi Medical Center |
2012-01 | |
| NCT00860366 | COMPLETED | Acute Ischemic Stroke |
Angel Chamorro, MD |
2011-06 | PHASE2; PHASE3 |
| NCT01797042 | COMPLETED | Obesity |
Rippe Lifestyle Institute |
2012-03 | |
| NCT01363869 | COMPLETED | Hyperuricemia; Gout |
Chiang Mai University |
2011-06 | |
| NCT01407874 | COMPLETED | Gout; Hyperuricemia; Arthritis; Joint Disease; Renal Insufficiency |
BioCryst Pharmaceuticals |
2011-09 | PHASE2 |
| NCT01825070 | COMPLETED | Inflammation |
Northumbria University |
2012-03 | |
| NCT00241839 | COMPLETED | Cardiovascular Diseases; Heart Diseases; Hypertension |
University of Florida |
2005-08 | PHASE3 |
| NCT04954560 | COMPLETED | Uric Acid Concentration, Serum, Quantitative Trait Locus 7 |
Medical University of Lodz |
2008-01-01 | |
| NCT00868673 | COMPLETED | Overweight and Obesity; Metabolic Syndrome; Hyperuricemia |
Instituto Nacional de Cardiologia Ignacio Chavez |
2009-03 | |
| NCT00793585 | COMPLETED | IgA Nephropathy |
Sun Yat-sen University |
2007-07 | |
| NCT00978653 | COMPLETED | Hyperuricemia; Chronic Kidney Disease |
Istanbul University |
2008-04 | |
| NCT00738842 | COMPLETED | Gout; Coronary Artery Disease |
AstraZeneca |
2008-05 | PHASE1 |
| NCT01931527 | COMPLETED | Obesity; Metabolic Syndrome; Hyperuricemia |
Washington University School of Medicine |
2006-07 | |
| NCT00230178 | COMPLETED | Tumor Lysis Syndrome; Cancer; Hyperuricemia |
Sanofi |
2004-04 | PHASE3 |
| NCT03921736 | COMPLETED | Hypertension; Hyperuricemia; Menopause |
Anna Posadzy-Małaczyńska |
2000-01-10 | PHASE4 |
| NCT00474396 | COMPLETED | Healthy |
Icahn School of Medicine at Mount Sinai |
2005-04 |
(data from https://clinicaltrials.gov, updated on 2026-05-29)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).